## SYSTEMIC IMMUNOMODULATORS

<table>
<thead>
<tr>
<th>Brand Names</th>
<th>Generic Names</th>
<th>Dosage Strengths</th>
<th>Dosage Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actemra®</td>
<td>tocilizumab</td>
<td>80mg/4ml, 200mg/10ml, 400mg/20ml</td>
<td>Single use vial, prefilled syringe</td>
</tr>
<tr>
<td>Arava®</td>
<td>leflunomide</td>
<td>10mg, 20mg, 100mg</td>
<td>Capsules</td>
</tr>
<tr>
<td>Arcalyst®</td>
<td>rilonacept</td>
<td>220mg</td>
<td>Single use vial</td>
</tr>
<tr>
<td>Cimzia®</td>
<td>certolizumab</td>
<td>200mg</td>
<td>Powder for SC injection, syringe kits, starter kits</td>
</tr>
<tr>
<td>Cosentyx®</td>
<td>secukinumab</td>
<td>150mg/ml, 150mg</td>
<td>Single use senoready® pen, single use prefilled syringe, single use vial (HCP admin only)</td>
</tr>
<tr>
<td>Enbrel®</td>
<td>etanercept</td>
<td>25mg, 50mg/ml</td>
<td>SC prefilled syringe, autoinjector, multiuse vials</td>
</tr>
<tr>
<td>Entyvio®</td>
<td>vedolizumab</td>
<td>300mg/20ml</td>
<td>Single use vial</td>
</tr>
<tr>
<td>Humira®</td>
<td>adalimumab</td>
<td>10mg/0.2ml, 20mg/0.4ml, 40mg/0.8ml</td>
<td>SC syringe, single use pens, starter packages</td>
</tr>
<tr>
<td>Ilaris®</td>
<td>canakinumab</td>
<td>180 mg reconstituted to 150 mg/ml</td>
<td>Single use vial</td>
</tr>
<tr>
<td>Inflectra® (biosimilar to Remicade)</td>
<td>Infliximab-dyyb</td>
<td>100 mg/20 ml</td>
<td>Intravenous infusion single dose vial</td>
</tr>
<tr>
<td>Kevzara®</td>
<td>Sarilumab</td>
<td>150 mg/1.14 mL, 200 mg/1.14 mL</td>
<td>single-dose pre-filled syringe</td>
</tr>
<tr>
<td>Kineret®</td>
<td>anakinra</td>
<td>100mg/0.67ml</td>
<td>SC prefilled syringe</td>
</tr>
<tr>
<td>Orencia®</td>
<td>abatacept</td>
<td>250 mg</td>
<td>Powder for injection, single dose vial, prefilled syringe, prefilled autoinjector</td>
</tr>
<tr>
<td>Otezla®</td>
<td>apremilast</td>
<td>30mg, two starter pack</td>
<td>tablet</td>
</tr>
<tr>
<td>Remicade®</td>
<td>infliximab</td>
<td>100 mg/20 ml</td>
<td>Single use vial</td>
</tr>
<tr>
<td>Renflexis (biosimilar to Remicade)</td>
<td>Infliximab-abda</td>
<td>100 mg/20 ml</td>
<td>Intravenous infusion single dose vial</td>
</tr>
<tr>
<td>Siliq®</td>
<td>brodalumab</td>
<td>210 mg/1.5 mL</td>
<td>single-dose pre-filled syringe</td>
</tr>
<tr>
<td>Simponi® /Simponi Aria®</td>
<td>golimumab</td>
<td>50mg/0.5ml, 50mg/4ml</td>
<td>Single dose prefilled syringe, Smartject autoinjector, IV solution</td>
</tr>
<tr>
<td>Stelara®</td>
<td>ustekinumab</td>
<td>45mg/0.5ml, 90mg/1ml</td>
<td>Single use vial, prefilled syringe</td>
</tr>
<tr>
<td>Taltz®</td>
<td>Ixekizumab</td>
<td>80mg/ml</td>
<td>Prefilled syringe, Prefilled auto-injector</td>
</tr>
<tr>
<td>Tremfya®</td>
<td>Guselkumab</td>
<td>100 mg/mL</td>
<td>single-dose pre-filled syringe</td>
</tr>
<tr>
<td>Xeljanz®/XR</td>
<td>tofacitinib</td>
<td>5mg tablet, 11mg tablet (XR)</td>
<td>Tablet, ER tablet</td>
</tr>
</tbody>
</table>

### Indications:

**Actemra® (tocilizumab)**

- Reduction in signs and symptoms of active Rheumatoid Arthritis (RA) in adult patients
- Juvenile Idiopathic Arthritis (JIA) in patients 2 years and older

**Arava® (leflunomide)**

- Reduction in signs and symptoms of active Rheumatoid Arthritis (RA) in adult patients
SYSTEMIC IMMUNOMODULATORS  
(cont.)

**Arcalyst® (rilonacept)**  
- Cryopyrin-Associated Periodic Syndromes (CAPS) in patients ≥ 12 years of age

**Cimzia® (certolizumab)**  
- Ankylosing spondylitis  
- Moderately to severely active Crohn’s Disease in adult patients  
- Moderately to severely active RA in combination with methotrexate  
- Psoriatic arthritis

**Cosentyx® (secukinumab)**  
- Moderate to severe Plaque psoriasis  
- Ankylosing spondylitis  
- Psoriatic arthritis

**Enbrel® (etanercept)**  
- Moderately to severely active RA  
- Juvenile Idiopathic Arthritis (JIA) in patients 2 years and older (previously listed as Juvenile Rheumatoid Arthritis (JRA))  
- Psoriatic arthritis  
- Ankylosing spondylitis  
- Moderate to severe chronic plaque psoriasis in patients 4 years and older

**Entyvio (vedolizumab)**  
- Moderately to severely active Crohn’s Disease in adult patients  
- Moderately to severely active Ulcerative Colitis in adult patients

**Humira® (adalimumab)**  
- Reduction in signs and symptoms of active RA in adult patients  
- Moderate to severe chronic plaque psoriasis  
- 100 mg/mL (JIA) in patients 2 years and older (previously listed as Juvenile Rheumatoid Arthritis (JRA))  
- Psoriatic arthritis  
- Ankylosing spondylitis  
- Moderately to severely active Crohn’s Disease in patients 6 years and older  
- Moderately to severely active Ulcerative Colitis  
- Hidradenitis Suppurativa  
- Uveitis

**Ilaris® (canakinumab)**  
- Juvenile Idiopathic Arthritis (JIA) in patients 2 years and older  
- Cryopyrin-Associated Periodic Syndromes (CAPS) in patients 4 years and older including:  
  - Familial Cold Autoinflammatory Syndrome (FCAS)  
  - Muckle-Wells Syndrome (MWS)  
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients  
- Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients  
- Familial Mediterranean Fever (FMF) in adult and pediatric patients
SYSTEMIC IMMUNOMODULATORS
(cont.)

**Kevzara® (sarilumab)**
- Moderately to severely active rheumatoid arthritis with or without methotrexate in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).

**Kineret® (anakinra)**
- Moderately to severely active RA
- Cryopyrin-Associated Periodic Syndromes (CAPS)

**Orencia® (abatacept)**
- Moderately to severely active RA
- Juvenile Idiopathic Arthritis (JIA) in patients 2 years and older (previously listed as Juvenile Rheumatoid Arthritis (JRA))
- Adult Psoriatic Arthritis (PsA)

**Otezla® (apremilast)**
- Psoriatic arthritis
- Plaque psoriasis

**Remicade® (infliximab)/Inflectra® (infliximab-dyyb)/Renflexis® (infliximab-abda)**
- Moderately to severely active RA in adult patients in combination with methotrexate
- Psoriatic arthritis
- Ankylosing spondylitis
- Plaque psoriasis
- Moderately to severely active Crohn’s Disease in patients 6 years and older
- Moderately to severely active Ulcerative Colitis in patients 6 years and older

**Siliq® (brodalumab)**
- Moderate to severe plaque psoriasis in adult patients

**Simponi® (golimumab)**
- Moderately to severely active Rheumatoid Arthritis (RA) in adults, in combination with methotrexate
- Active Psoriatic Arthritis (PsA) in adults, alone or in combination with methotrexate
- Active Ankylosing Spondylitis in adults (AS)
- Moderately to severely active Ulcerative Colitis

**Simponi Aria® (golimumab)**
- Moderately to severely active Rheumatoid Arthritis (RA) in adults, in combination with methotrexate

**Stelara® (ustekinumab)**
- Moderate to severe Plaque psoriasis in patients 12 years and older
- Psoriatic arthritis
- Moderately to severely active Crohn’s Disease who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed a tumor necrosis factor (TNF) blocker or failed or were intolerant to treatment with one or more TNF blockers

**Taltz® (ixekizumab)**
- Moderate to severe Plaque psoriasis

**Tremfya® (guselkumab)**
- Moderate-to-severe plaque psoriasis

**Xeljanz®/XR (tofacitinib)**
- Moderately to severely active Rheumatoid Arthritis (RA) in adults alone or in combination with methotrexate or other DMARDS
SYSTEMIC IMMUNOMODULATORS (cont.)

Length of authorization:
- Initial 3 months for Crohn’s or Ulcerative Colitis
- 1 year for all other indications
- Renewal 1 year dependent upon medical records supporting response to therapy and review of Rx history

Criteria for Approval:
- Prior approval will only be granted for the approved FDA indications listed above, AND
- Must be prescribed by a rheumatologist, gastroenterologist or dermatologist based on the approved FDA indication

Ankylosing Spondylitis
1. Trial and failure required with an NSAID

Juvenile Idiopathic Arthritis (JIA)/ Juvenile Idiopathic Arthritis (JIA)
1. Trial and failure of, contraindication, or adverse reaction to methotrexate

Moderately to severely active Crohn’s Disease (all of the following must be met):
1. Trial and failure of a compliant regimen of oral corticosteroids (moderate to severe CD) unless contraindicated or intravenous corticosteroids (severe and fulminant CD or failure to respond to oral corticosteroids)

Moderately to severely active ulcerative colitis (all of the following must be met):
1. Trial and failure of a compliant regimen of oral or rectal aminosalicylates (i.e., sulfasalazine or mesalamine) for two consecutive months, AND
2. Trial and failure of a compliant regimen of oral corticosteroids (for moderate to severe CD) unless contraindicated, or intravenous corticosteroids (for severe and fulminant CD or failure to respond to oral corticosteroids), AND
3. Trial and failure of a compliant regimen of azathioprine or mercaptopurine for three consecutive months

Moderate to severe chronic plaque psoriasis:
1. Must have a previous failure on a topical psoriasis agent

Psoriatic Arthritis
1. Trial and failure required with methotrexate first or in combination with methotrexate if appropriate

Rheumatoid Arthritis:
1. Trial and failure of, contraindication, or adverse reaction to methotrexate and at least one other DMARD (sulfasalazine, hydroxychloroquine, minocycline)
SYSTEMIC IMMUNOMODULATORS
(cont.)

Criteria for Denial:
1. Moderate to severe heart failure (New York Heart Association [NYHA] Functional Class III/IV)
2. Live vaccines should not be given concurrently
3. Presence of active infections
4. Current or recent malignancy
5. Concomitant treatment with azathioprine or 6-mercaptopurine due to increased risk of fatal hepatosplenic T-cell lymphomas (for Remicade® request only)
6. Pregnancy (for Arava® request only)
7. Concomitant use with other systemic immunomodulators
8. Concurrent diagnosis of irritable bowel syndrome (for Cosentyx® only)

Non-Preferred drugs on the Preferred Drug List (PDL) require additional Prior Approval (PA).

References:
Available upon request.

<table>
<thead>
<tr>
<th>Reviewed by:</th>
<th>Reason for Review:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacy &amp; Therapeutic Committee</td>
<td>New</td>
<td>11/6/08</td>
</tr>
<tr>
<td>Commissioner</td>
<td>Approval</td>
<td>12/1/08</td>
</tr>
<tr>
<td>DUR Committee</td>
<td>Revision</td>
<td>3/22/10</td>
</tr>
<tr>
<td>Commissioner</td>
<td>Approval</td>
<td>4/30/10</td>
</tr>
<tr>
<td>DUR Committee</td>
<td>Revision</td>
<td>3/23/11</td>
</tr>
<tr>
<td>Commissioner</td>
<td>Approval</td>
<td>6/7/11</td>
</tr>
<tr>
<td>DUR Board</td>
<td>Revision</td>
<td>5/12/15</td>
</tr>
<tr>
<td>Commissioner</td>
<td>Approval</td>
<td>6/30/15</td>
</tr>
<tr>
<td>DUR Board</td>
<td>Revision</td>
<td>5/31/16</td>
</tr>
<tr>
<td>Commissioner</td>
<td>Approval</td>
<td>6/18/16</td>
</tr>
<tr>
<td>DUR Board</td>
<td>Revision</td>
<td>10/11/16</td>
</tr>
<tr>
<td>Commissioner</td>
<td>Approval</td>
<td>11/22/16</td>
</tr>
<tr>
<td>DUR Board</td>
<td>Revision</td>
<td>10/24/17</td>
</tr>
<tr>
<td>Commissioner</td>
<td>Approval</td>
<td>12/5/17</td>
</tr>
</tbody>
</table>